Leerink Partners Keeps Their Buy Rating on Seagen (SGEN)

Leerink Partners analyst Andrew Berens maintained a Buy rating on Seagen (SGENResearch Report) on April 10. The company’s shares closed last Monday at $144.29.

According to, Berens is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.4% and a 43.6% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Deciphera Pharmaceuticals.

Seagen has an analyst consensus of Moderate Buy, with a price target consensus of $157.08, representing a 4.5% upside. In a report released yesterday, Berenberg Bank also maintained a Buy rating on the stock with a $180.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $192.79 and a one-year low of $117.46. Currently, Seagen has an average volume of 1.13M.

Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SGEN in relation to earlier this year. Last month, Nancy Simonian, a Director at SGEN bought 25,000 shares for a total of $501,000.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Washington-based Seagen, Inc. is a biotechnology company, which is focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev.

Read More on SGEN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More